Timothy S. Anderson, MD, MAS; John Z. Ayanian, MD, MPP; Jeffrey Souza, MA; et al.
This study evaluates whether patients enrolled in trials of aducanumab, EMERGE and ENGAGE, were representative of patients with dementia enrolled in Medicare by estimating the proportions of Medicare beneficiaries with Alzheimer disease (AD) or mild cognitive impairment (MCI) who would have been excluded from these trials.